Dinutuximab beta combined with two induction chemotherapy regimens for newly diagnosed high-risk neuroblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open‑label Phase 1 dual‑cohort study adding dinutuximab beta to one of two standard induction chemotherapy regimens (GPOH or rapid COJEC) in newly diagnosed high‑risk neuroblastoma. A dose‑escalation phase will determine the recommended Phase II dose or maximum tolerated dose for dinutuximab beta with each chemotherapy backbone, followed by a confirmation cohort of 10 evaluable patients per regimen. Treatment courses differ by regimen (GPOH: 10 mg/m2 × 5 days every 21 days; rapid COJEC: 10 mg/m2 × 3 days every 10 days) and total induction lasts about 126 days (GPOH) or 80 days (rapid COJEC). Up to 38 evaluable patients will be enrolled across escalation and confirmation parts, with safety follow‑up 30 days after the last dinutuximab beta dose and longer clinical follow‑up per local high‑risk neuroblastoma protocols.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Established diagnosis of neuroblastoma Stage M, according to the SIOPEN modified International Neuroblastoma Risk Group (INRG) and to the INSS criteria (Appendix 1).
2. Age ≥18 months and \<18 years.
3. Body weight \>12 kg.
4. Alanine transaminase and aspartate aminotransferase \<10 × upper limit of normal (ULN), total bilirubin \<1.5 × ULN based on age specific reference ranges.
5. Calculated glomerular filtration rate \> 60 mL/min/1.73 m2 or serum creatinine \<1.5 × ULN corrected for age.
6. Shortening fraction (SF) ≥27% and/or left ventricular ejection fraction (LVEF) \>50% as determined by echocardiography or MUGA.
7. Able to comply with scheduled follow-up and study procedures.
8. Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study specific screening procedures are conducted, according to local, regional or national law and legislation.

Exclusion Criteria:

1. Previous cancer-specific treatment for neuroblastoma.
2. Current use of a prohibited medication or requires any of these medications during the study:

   1. Treatment with corticosteroids is not allowed within 2 weeks prior to the first block of chemotherapy and until 1 week after the last treatment course with dinutuximab beta, except for life-threatening conditions.
   2. Vaccinations (including seasonal influenza) are not allowed during administration of dinutuximab beta and until 10 weeks after last treatment course.
   3. Concomitant use of intravenous (IV) immunoglobulins is not allowed.
   4. Concomitant use of cardioprotectant dexrazoxane is not allowed.
3. Pregnancy or positive pregnancy test in females of childbearing potential.
4. Breast feeding.
5. Sexually active participants not willing to use highly effective contraceptive method
6. Major surgery within 21 days prior to the first treatment dose
7. History or documented evidence of severe acute or chronic infection or infectious illness requiring parenteral therapy unless fully healed
8. Patients with spinal cord involvement
9. Any other disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug
10. Have a known immediate or delayed hypersensitivity reaction to study drugs

Where it's running

• Princess Maxima center for pediatric oncology
  Utrecht, Utrecht, Netherlands Recruiting

Study contacts

• Principal investigator: Holger Lode, MD, PhD — Princess Maxima Center for Pediatric Oncology
• Study coordinator: Jorden Veeneman, PhD
• Email: trialmanagement@prinsesmaximacentrum.nl
• Phone: +31650173417

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• rhIL-15 with dinutuximab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma in children and young adults

  This trial will test whether adding rhIL-15 to dinutuximab with irinotecan and temozolomide helps children and young adults (ages 3-35) whose neuroblastoma has returned or not responded to prior treatments.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06995872

• STING: sequential temozolomide, irinotecan, donor NK cells, and dinutuximab for neuroblastoma

  This will test whether adding donor TGF‑beta‑imprinted NK cells to dinutuximab plus temozolomide, irinotecan, and GM‑CSF helps children and young adults with relapsed or refractory high‑risk neuroblastoma.

  Recruiting at 8 sites Phase 2 New Approaches to Neuroblastoma Therapy Consortium · Los Angeles, California and 12 other locations · NCT06450041

• Combining dinutuximab with chemotherapy and surgery for treating high-risk neuroblastoma in children

  This study is testing if adding a new medicine called dinutuximab to regular chemotherapy and surgery can help children with high-risk neuroblastoma live longer without their cancer coming back.

  Recruiting at 177 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 179 other locations · NCT06172296

• Using expanded gamma delta T cells with chemotherapy for treating relapsed neuroblastoma and osteosarcoma

  This study is testing if a new treatment using special immune cells along with chemotherapy can help children with relapsed neuroblastoma and osteosarcoma feel better and improve their chances of recovery.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT05400603

• Neuroblastoma patients' genomic and biological profile study

  This multicenter, prospective study tests profiles from blood, tumor tissue, and bone marrow to understand neuroblastoma in diagnosed, relapsed, or refractory patients.

  Recruiting at 35 sites Istituto Giannina Gaslini · Ancona and 34 other locations · NCT07881172

• Dinutuximab-beta with chemotherapy in newly diagnosed high-risk neuroblastoma

  This pilot study tests whether adding the antibody dinutuximab-beta to standard induction chemotherapy is safe and helps shrink tumors in kids and young adults with newly diagnosed high-risk neuroblastoma.

  Recruiting at 2 sites Phase 1 Chang Gung Memorial Hospital · Taipei, Taiwan and 1 other locations · NCT07688252

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.